The Latest Breaking News from JNJ

Despite volatile market conditions owing to the Russia-Ukraine war, supply chain bottlenecks, high inflation, and imminent aggressive federal interest rate increases, the Dow Jones Industrial Average has managed to advance over the past month on an improving labor market and strong corporate results. So, we think it could be wise…

Alabama reached $276 million in settlements with Johnson & Johnson (NYSE:JNJ), McKesson Corporation (NYSE:MCK), and Endo International Plc (NASDAQ:ENDP), resolving claims on the opioid addiction crisis, the state attorney general said. McKesson will pay $141 million. JNJ and Endo will pay $70.3 million and $25 million, respectively, Alabama Attorney General Steve Marshall said in a statement.  The three…

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 11 strange trades.

Worries over intensifying supply disruptions with growing sanctions on Russia have shaken investors. Furthermore, rising crude oil prices coupled with record-high inflation have given rise to recession fears. Thus, we think it could be wise to bet on ultra-safe dividend aristocrats Johnson & Johnson (JNJ), Walmart (WMT), PepsiCo (PEP), Abbott…

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Tuesday.

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Tuesday.

BeiGene Ltd (NASDAQ:BGNE) shared updated data analyses from the Phase 3 RATIONALE-309 trial of tislelizumab combined with chemotherapy versus chemotherapy plus placebo in first-line recurrent or metastatic nasopharyngeal cancer. Updated efficacy analyses showed that, at a median follow-up of 15.5 months, tislelizumab/chemotherapy combo demonstrated a clinically significant progression-free survival (PFS) benefit over chemotherapy…

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 400 points on Tuesday.

Johnson & Johnson slashed its 2022 guidance on Tuesday and cut its Covid vaccines outlook entirely — but JNJ stock popped at the open.

Johnson & Johnson (NYSE:JNJ) has reported Q1 FY22 adjusted earnings of $2.67 per share, up 3.1% Y/Y and ahead of the consensus of $2.61. Net sales increased 5% Y/Y (7.9% on an operational basis) to $23.43 billion, missing the consensus of $23.67 billion. Pharmaceuticals contributed $12.87 billion in sales, +9.3%, due to Darzalex…

  Johnson & Johnson (NYSE:JNJ) reported its Q1 earnings results on Tuesday, April 19, 2022 at 06:30 AM. Here's what investors need to know about the announcement.